Determination of SCH 211803 by nanoelectrospray infusion mass spectrometry: evaluation of matrix effect and comparison with liquid chromatography-tandem mass spectrometry.
A high throughput assay for SCH 211803, an M2 muscarinic receptor antagonist in human plasma using nanoelectrospray infusion tandem mass spectrometry is described. Sample processing consisted of protein precipitation followed by solid phase extraction using octadecasilyl resin-filled pipette tips on a liquid handling robotic system. The sample extracts were infused directly to the mass spectrometer using a nanoelectrospray interface in a silicon chip format. SCH 211803 was quantified in plasma over the concentration range of 1-1000 ng/mL. In comparison with a liquid chromatography-tandem mass spectrometry assay, the nanoelectrospray method has comparable accuracy, precision and limit of quantitation, with a nine-fold improvement in sample throughput. Using the nanoelectrospray assay, ion suppression was evaluated and found to be 15%. This represented a four-fold reduction in matrix suppression when compared to a conventional electrospray source operating in the flow injection analysis mode at a flow rate common for LC-MS/MS analysis.
Schering-Plough Research Institute, Kenilworth, NJ 07033, USA.
Jiwen
J
Chen
Liyu
L
Yang
James T
JT
Kapron
Li
L
Ma
Ellan
E
Pace
Colleen K
CK
Van Pelt
Patrick J
PJ
Rudewicz
D000818:Animals; D006801:Humans; D018727:Muscarinic Antagonists / Q000097:blood*; D036103:Nanotechnology; D010880:Piperidines / Q000097:blood*; D015203:Reproducibility of Results; D021241:Spectrometry, Mass, Electrospray Ionization / Q000379:methods*
C483563:1'-(2-amino-3-methylbenzoyl)-4-(((3-chlorophenyl)sulfonyl)phenyl)methyl-1,4'-bipiperidine hydrochloride; D018727:Muscarinic Antagonists; D010880:Piperidines